logo
  

Nature's Miracle To Acquire Agrify - Quick Facts

Nature's Miracle Holding Inc. (NMHI) has entered into a term sheet to acquire 100% of all the outstanding shares of Agrify Corporation (AGFY). Nature's Miracle expects to acquire Agrify through issuing shares of Nature's Miracle common stock which would result in Nature's Miracle owning Agrify. Each shareholder of Agrify would be expected to receive approximately 0.45 of a share of Nature's Miracle common stock for each share of Agrify common stock. AGFY equity is valued at $6.35 million, or $0.4185 per share. Also, Nature's Miracle will buy all of the current debt of Agrify held by two entities controlled by Raymond Chang with a combination of cash and Nature's Miracle stock.

Raymond Chang, CEO of Agrify, will assume the role as President of the Agrify division of Nature's Miracle and will join the board of Nature's Miracle.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast. Shares of Marks and Spencer Group Plc or M&S were gaining more than 7 percent in the morning trading in London after the retail major reported Wednesday significantly higher profit and sales in its fiscal 2024. The company also announced a dividend, and said it is confident to make further progress in 2025 and beyond.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT